What is TT3-LITE Regimen (L-TT3) used for?

TT3-LITE Regimen (L-TT3) is indicated for Hypothyroidism.

Who makes TT3-LITE Regimen (L-TT3)?

TT3-LITE Regimen (L-TT3) is developed by University of Arkansas.

What development phase is TT3-LITE Regimen (L-TT3) in?

TT3-LITE Regimen (L-TT3) is in Phase 3.

What are the side effects of TT3-LITE Regimen (L-TT3)?

Common side effects include Headache, Nausea, Fatigue.

Last reviewed 2026-04-23 · How we verify

TT3-LITE Regimen (L-TT3)

University of Arkansas · Phase 3 active Small molecule

L-TT3 is a thyroid hormone replacement therapy that mimics the natural thyroid hormone, T3.

L-TT3 is a thyroid hormone replacement therapy that mimics the natural thyroid hormone, T3. Used for Hypothyroidism.

At a glance

Generic name	TT3-LITE Regimen (L-TT3)
Also known as	Velcade (bortezomib), Melphalan, Dexamethasone, Thalidomide, Cisplatin
Sponsor	University of Arkansas
Drug class	Thyroid hormone replacement therapy
Target	Thyroid hormone receptor
Modality	Small molecule
Therapeutic area	Endocrinology
Phase	Phase 3

Mechanism of action

L-TT3 works by replacing the thyroid hormone that is deficient in the body, thereby regulating metabolism and energy production. It is designed to mimic the natural T3 hormone, which is essential for various bodily functions. By replacing this hormone, L-TT3 helps to alleviate symptoms of hypothyroidism.

Approved indications

Hypothyroidism

Common side effects

Headache
Nausea
Fatigue

Key clinical trials

UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results